Asian Phytoceuticals Public (APCO) Fundamentals 2026 — P/E 28.9x, Revenue Analysis | SniperIQ
Asian Phytoceuticals Public (APCO) is a TH-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ฿1.6B, trading at ฿2.72 on the SET. This SniperIQ fundamentals page covers Asian Phytoceuticals Public's valuation (P/E 28.9x, P/B 2.8x), profitability (net margin 29.9%), revenue (฿200M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Asian Phytoceuticals Public's market cap?
Asian Phytoceuticals Public (APCO) has a market capitalization of approximately ฿1.6B, trading at ฿2.72 on the SET. Market cap moves with the live share price.
What is Asian Phytoceuticals Public's P/E ratio?
Asian Phytoceuticals Public's trailing twelve-month P/E ratio is 28.9x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Asian Phytoceuticals Public?
Asian Phytoceuticals Public runs a net profit margin of 29.9%, a gross margin of 84.4%, and an operating margin of 28.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Asian Phytoceuticals Public generate?
Asian Phytoceuticals Public reported revenue of ฿200M for fiscal year 2025, with net income of ฿55M and earnings per share (EPS) of 0.0924. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Asian Phytoceuticals Public pay a dividend?
Asian Phytoceuticals Public offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Asian Phytoceuticals Public financially healthy?
Asian Phytoceuticals Public carries a debt-to-equity ratio of 0.02x and a current ratio of 10.82x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Asian Phytoceuticals Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Asian Phytoceuticals Public (APCO) the key facts are: market cap ฿1.6B, P/E 28.9x, revenue ฿200M, 52-week range 2.48-3.44. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Asian Phytoceuticals Public's full fundamentals live
Get Asian Phytoceuticals Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.